Novo Nordisk A S annual book value per share
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Book Value Per Share Growth & History (NVO)
Novo Nordisk A S's book value per share was DKK 43.66 for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | DKK 43.66 | DKK 11.36 | +35.15% |
| 2024 | 2024-12-31 | DKK 32.31 | DKK 8.41 | +35.17% |
| 2023 | 2023-12-31 | DKK 23.90 | DKK 5.35 | +28.84% |
| 2022 | 2022-12-31 | DKK 18.55 | DKK 3.24 | +21.15% |
| 2021 | 2021-12-31 | DKK 15.31 | DKK 1.84 | +13.65% |
| 2020 | 2020-12-31 | DKK 13.47 | DKK 1.47 | +12.29% |
| 2019 | 2019-12-31 | DKK 12.00 | — | — |
Novo Nordisk A S quarterly book value per share
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | DKK 50.01 | DKK 12.17 | +32.15% |
| Q1 2026 | 2026-03-31 | DKK 45.76 | — | — |
| Q4 2025 | 2025-12-31 | DKK 43.66 | DKK 11.36 | +35.15% |
| Q3 2025 | 2025-09-30 | DKK 38.25 | — | — |
| Q2 2025 | 2025-06-30 | DKK 37.84 | — | — |
| Q4 2024 | 2024-12-31 | DKK 32.31 | DKK 8.41 | +35.17% |
| Q4 2023 | 2023-12-31 | DKK 23.90 | DKK 5.35 | +28.84% |
| Q4 2022 | 2022-12-31 | DKK 18.55 | DKK 3.24 | +21.15% |
| Q4 2021 | 2021-12-31 | DKK 15.31 | — | — |
Novo Nordisk A S book value per share trends
Over the last five fiscal years, Novo Nordisk A S's book value per share increased from DKK 13.47 to DKK 43.66, a change of DKK 30.19. The latest reported quarter, Q2 2026, shows DKK 50.01.
About the metric
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
Calculation and source
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...